Etretinate
As of the edition of 20 October 2026, Etretinate is a small molecule: withdrawn from the market in 1989; acts on RARA, RARB and RARG and 3 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 1989
- Kind
- Small molecule
- Brand name
- Tegison
- First approved
- 30 September 1986 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Roche
- Withdrawn from market
- 1 January 1989 (in some regions)
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Etretinate.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Originator | 1986 to now |